{"entity":{"id":"nct05586074","kind":"trial","name":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","aka":[],"tldr":"A phase 3 trial testing Clifutinib in acute myeloid leukaemia, now recruiting.","summary":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML is a phase 3 interventional study registered as NCT05586074, led by Sunshine Lake Pharma, and recruiting on the registry. Official title: HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia: a Multicenter, Open-label, Randomised Phase 3 Trial. Planned enrolment is 324 participants (estimated). The study started in 2023-03-03 and primary completion is expected in 2027-11-30. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05586074","url":"https://clinicaltrials.gov/study/NCT05586074"}],"tags":["ctgov-ingest"],"related":[],"cancers":["aml","aml-flt3"],"sections":[],"technologies":[],"targets":[],"drugs":["clifutinib"],"companies":["sunshine-lake-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05586074","phase":"3","setting":"HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial","sponsor":"Sunshine Lake Pharma","started":"2023-03-03","startedType":"actual","enrolled":324,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05586074/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/"}],"drug":[{"id":"clifutinib","kind":"drug","name":"Clifutinib","route":"/drugs/clifutinib/"}],"company":[{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","route":"/companies/sunshine-lake-pharma/"}]}}